Lantheus Holdings, Inc. (LNTH): Cost of Revenue
$599.66M
Year ended 2025-12-31
$620.29M
Trailing 12 months to 2026-06-30
+19.3%
3-year compound annual growth
+24.5%
5-year compound annual growth
+14.3%
10-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $599.66M | +9.9% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $545.62M | -7.0% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $586.89M | +66.1% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $353.36M | +48.8% | 2025-02-26, From 2022-01-01 |
| 2021-12-31 | $237.51M | +18.4% | 2024-02-22, From 2021-01-01 |
| 2020-12-31 | $200.65M | +16.3% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $172.53M | +2.4% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $168.49M | -0.4% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $169.24M | +3.2% | 2020-02-25, From 2017-01-01 |
| 2016-12-31 | $164.07M | +3.9% | 2019-02-20, From 2016-01-01 |
| 2015-12-31 | $157.94M | -10.3% | 2018-02-26, From 2015-01-01 |
| 2014-12-31 | $176.08M | -14.7% | 2017-02-23, From 2014-01-01 |
| 2013-12-31 | $206.31M | n/a | 2016-03-02, From 2013-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | 2025-12-31 | $599.66M | +9.9% |
| Neogen Corp (NEOG) | 2026-05-31 | $461.90M | -2.4% |
| Myriad Genetics Inc (MYGN) | 2025-12-31 | $247.90M | -1.7% |
| Idexx Laboratories Inc (IDXX) | 2025-12-31 | $1.64B | +8.3% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $27.08M | -11.3% |
| Immucell Corp (ICCC) | 2025-12-31 | $16.20M | -12.7% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | $3.30M | -10.9% |
| Anbio Biotechnology (NNNN) | 2025-12-31 | $1.10M | -52.0% |
| Biomerica Inc (BMRA) | 2026-05-31 | $4.09M | -15.0% |
Compare LNTH, NEOG, MYGN, IDXX side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗